Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'An incredible privilege and responsibility': Artemis 2's Christina Koch is ready to become the 1st woman to fly around the moon - 2Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- 3Dependable Savvy Locks to Update Your Home Security
- 4Germany records first wolf bite on human since repopulation
- 5Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- What is the Significant Tech Expertise to Master Today?
- Farmers worry about rising cost of fertiliser
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- Pfizer says patient dies after receiving hemophilia drug in trial
- Vice President Dick Cheney’s life followed the arc of the biggest breakthroughs in cardiovascular medicine
- China's Normal Ponders: A Visual Excursion
- World's oldest known tortoise still very much alive despite rumor to the contrary
- 4 Electric Vehicle Brands: Execution, Unwavering quality, and Development
